Urinary orosomucoid: a novel, early biomarker of sepsis with promising diagnostic performance

Kabos, Peter; Szirmay, Balázs; Horváth‐Szalai, Zoltán; Ludány, Andrea; Kovaćs, Gábor L.; Miseta, Attila; Kőszegi, Tamás; Mühl, Diána

doi:10.1515/cclm-2016-0840

Cited by 16 publications

(11 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In order to investigate the potential clinical utility of u-CYSC measurements, a group of patients with sepsis-related AKI (n = 33), patients with chronic hypertension (n = 43) and Type 2 diabetic patients (n = 41), were also included. AKI in septic patients was established using the Kidney Disease Improving Global Outcomes guideline [12] supported by serum CYSC concentrations, similarly to others [13][14][15]. Inclusion criteria for the chronic hypertension and diabetic patient groups were: established clinical diagnosis of their treated disease, the lack of acute inflammatory conditions and other chronic disorders such as autoimmune diseases or tumors.…”

Section: Subjectsmentioning

confidence: 99%

Novel Automated Immune Turbidimetric Assay for Routine Urinary Cystatin-C Determinations

et al. 2018

Self Cite

View full text Add to dashboard Cite

Aim: There is no commercially available urinary cystatin-C (u-CYSC) test in the market. Therefore, we optimized and validated an automated immune turbidimetric test for u-CYSC measurements and investigated u-CYSC concentrations in acute and chronic diseases which might lead to renal tubular disorders. Materials & methods: A particle-enhanced immune turbidimetric assay was adapted and validated on a Cobas 8000/c502 analyzer. Urine samples of different patient groups were also analyzed. Results: Our method showed excellent analytical performance. U-CYSC/u-creatinine (u-CREAT) was higher in sepsis-related acute kidney injury group (p < 0.001) compared with controls and to patients with chronic hypertension and Type 2 diabetes. Conclusion: We validated a fast, sensitive, fully automated u-CYSC assay which is ideal for routine use and might be a potential complementary laboratory test to evaluate renal tubular function.

show abstract

Section: Subjectsmentioning

confidence: 99%

Novel Automated Immune Turbidimetric Assay for Routine Urinary Cystatin-C Determinations

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…The several-fold elevation found in active CD might be in accordance with the former observations related to other inflammatory disorders. [12][13][14]16,28 This assumption is confirmed by the significant correlations of u-ORM with conventional inflammatory parameters.…”

Section: T a B L E 1 Montreal Classification Of Patientsmentioning

confidence: 68%

“…Elevated u‐ORM excretion is supposed to be in association with the activation of the immune system. The several‐fold elevation found in active CD might be in accordance with the former observations related to other inflammatory disorders . This assumption is confirmed by the significant correlations of u‐ORM with conventional inflammatory parameters.…”

Section: Discussionmentioning

confidence: 96%

Elevated urinary orosomucoid excretion as a novel biomarker in Crohn’s disease

Szirmay

Tárnok

Patrícia

et al. 2018

Eur J Clin Investigation

Self Cite

View full text Add to dashboard Cite

Background Laboratory markers are essential tools in the follow‐up of patients with Crohn's disease (CD). Our aim was to investigate urinary concentrations of orosomucoid in relation to the inflammatory activity of CD and to compare it with clinical indices and conventional laboratory parameters. Materials and methods Blood and urine samples of 86 patients (55 adults and 31 children) with CD and 68 healthy individuals (38 adults and 30 children) as controls were analysed. Patients were categorized according to their clinical scores (Harvey‐Bradshaw Index [HBI] or Pediatric Crohn's Disease Activity Index [PCDAI]). Urinary orosomucoid (u‐ORM) was determined by automated immune turbidimetric assay, and values were referred to urinary creatinine (u‐ORM/u‐CREAT, mg/mmol). Results U‐ORM/u‐CREAT values were seven times higher in children with active CD (0.50 vs 0.07 mg/mmol, P < 0.001) and two times higher in adults (0.32 vs 0.14 mg/mmol, P = 0.01) compared with patients with inactive disease. U‐ORM/u‐CREAT showed good correlation with conventional inflammatory markers (hs‐CRP, serum ORM; P < 0.01) and activity indices (HBI, P = 0.018; PCDAI, P < 0.001). U‐ORM/u‐CREAT had similar discriminative performance to hs‐CRP and serum ORM in the differentiation of active from inactive paediatric CD patients. Conclusions Our findings suggest that u‐ORM/u‐CREAT might serve as a valuable additional marker in the follow‐up of CD patients, especially in children for whom the non‐invasive sampling is a further advantage.

show abstract

“…ORM proteins could be applied as diagnostic markers for the early events of many pathological states. Elevated urinary ORM levels have been reported as biomarkers for multiple carcinomas and inflammatory diseases such as psoriasis, Crohn disease, and sepsis (39)(40)(41)(42)(43). Notably, Park et al (44) demonstrated that the urinary levels of ORM1 and ORM2 were increased in patients with RA and correlated with disease activity.…”

Section: Discussionmentioning

confidence: 99%

Urinary Proteomics Identifying Novel Biomarkers for the Diagnosis of Adult-Onset Still’s Disease

et al. 2020

View full text Add to dashboard Cite

Adult-onset Still's disease (AOSD) is a systemic, multigenic autoinflammatory disease, and the diagnosis of AOSD must rule out neoplasms, infections, and other autoimmune diseases. Development of a rapid and efficient but non-invasive diagnosis method is urgently needed for improving AOSD therapy. In this study, we first performed a urinary proteomic study using isobaric tags for relative and absolute quantification (iTRAQ) labeling combined with liquid chromatography-tandem mass spectrometry analysis in patients with AOSD and healthy control (HC) subjects. The urinary proteins were enriched in pathways of the innate immune system and neutrophil degranulation, and we identified that the α-1-acid glycoprotein 1 (LRG1), orosomucoid 1 (ORM1), and ORM2 proteins were highly expressed in patients with AOSD. The elevated urine levels of LRG1, ORM1, and ORM2 were further validated by enzyme-linked immunosorbent assay in active patients with AOSD, disease controls, and HC subjects. Receiver operating characteristic curves showed that the areas under the curve of LRG1, ORM1, and ORM2 were 0.700, 0.837, and 0.736, respectively (all p < 0.05). Furthermore, we found that the urine levels of LRG1, ORM1, and ORM2 were positively correlated with the systemic score and erythrocyte sedimentation rate and that the urine levels of LRG1 were positively correlated with interleukin 1β (IL-1β), IL-6, and IL-18 levels, whereas the urine levels of ORM1 were positively correlated with the IL-1β level. Together, our study identified novel urinary markers for non-invasive and simple screening of AOSD.

show abstract

Urinary orosomucoid: a novel, early biomarker of sepsis with promising diagnostic performance

Abstract: The early and relevant increase of u-ORM in sepsis suggests that it might be a promising novel marker of sepsis and could be a valuable part of routine laboratory and clinical practice.

Cited by 16 publications

References 36 publications

Novel Automated Immune Turbidimetric Assay for Routine Urinary Cystatin-C Determinations

Novel Automated Immune Turbidimetric Assay for Routine Urinary Cystatin-C Determinations

Elevated urinary orosomucoid excretion as a novel biomarker in Crohn’s disease

Urinary Proteomics Identifying Novel Biomarkers for the Diagnosis of Adult-Onset Still’s Disease

Contact Info

Product

Resources

About